Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 6/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 7/20 | 0.33 |
| ▸ | FAAH | O00519 | 4/20 | 0.33 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4460742 | 1.00 | EPHX1 (0.38) | EPHX1CES2THRBCTSLCTSB | |
| SCHEMBL4466652 | 1.00 | EPHX1 (0.38) | EPHX1CES2THRBCTSLCTSB | |
| SCHEMBL1119763 | 0.98 | — | — | |
| SCHEMBL2892756 | 0.91 | — | — | |
| SCHEMBL384256 | 0.88 | — | — | |
| SCHEMBL956731 | 0.80 | — | — | |
| SCHEMBL2058598 | 0.72 | SLC2A1 (0.38) | — | |
| SCHEMBL2018319 | 0.69 | — | — | |
| SCHEMBL7611194 | 0.69 | TSHR (0.42) | EPHX1CES2THRBCTSLCTSB | |
| SCHEMBL5586092 | 0.69 | TSHR (0.42) | EPHX1CES2THRBCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116355117-A | Terminal functionalized high cis-rare earth conjugated diene rubber and preparation method thereof | 青岛科技大学 | 2023-06-30 | — | — | CN | disclosed |
| US-9234256-B2 | Scavenger supports and the use thereof in a process for the extraction of metals | JOHNSON MATTHEY FINLAND OY (FI) | 2016-01-12 | — | — | US | disclosed |
| US-9045403-B2 | Geranyl geranyl acetone (GGA) derivatives and compositions thereof | COYOTE PHARMACEUTICALS, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-8968591-B2 | Organic piezoelectric material, ultrasound transducer, ultrasound probe, and ultrasound medical diagnostic imaging system | KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20150025077-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2015-01-22 | — | — | US | disclosed |
| WO-2014163643-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014151719-A1 | SUBLINGUAL FORMULATIONS INCLUDING GERANYLGERANYLACETONE AND GERANYLGERANYLACETONE DERIVATIVES | COYOTE PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-8652335-B2 | Scavenger supports and the use thereof in a process for the extraction of metals | JOHNSON MATTHEY FINLAND OY (FI) | 2014-02-18 | — | — | US | disclosed |
| US-20130296323-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| WO-2013130654-A1 | GGA AND GGA DERIVATIVES, COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | COYOTE PHARMACEUTICALS, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| EP-1769094-A2 | SCAVENGER SUPPORTS WITH AMINO-FUNCTIONALISED PENDANT KETOESTER OR KETOAMIDE GROUPS FOR REMOVING METALS FROM SOLUTIONS | Reaxa Limited (GB) | 2007-04-04 | — | — | EP | disclosed |
| WO-2005123971-A2 | SCAVENGER SUPPORTS WITH AMINO-FUNCTIONALISED PENDANT KETOESTER OR KETOMIDE GROUPS FOR REMOVING METALS FROM SOLUTIONS | REAXA LIMITED (GB) | 2005-12-29 | — | — | WO | disclosed |
| EP-1534681-A1 | SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-06-01 | — | — | EP | disclosed |
| EP-1524289-A1 | POLYMERIZABLE COMPOSITION, OPTICAL MATERIAL COMPRISING THE COMPOSITION AND METHOD FOR PRODUCING THE MATERIAL | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2005-04-20 | — | — | EP | disclosed |
| US-20040254258-A1 | Polymerizable composition, optical material comprising the composition and method for producing the material | MITSUBISHI GAS CHEMICAL CO., LTD. (JP) | 2004-12-16 | — | — | US | disclosed |
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-04-15 | — | — | US | disclosed |
| WO-2004002960-A1 | SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-01-08 | — | — | WO | disclosed |
| US-4642104-A | Urethral catheter capable of preventing urinary tract infection and process for producing the same | UNITIKA LTD. (JP) | 1987-02-10 | — | — | US | disclosed |
| US-4539234-A | Urethral catheter capable of preventing urinary tract infection and process for producing the same | UNITIKA LTD. (JP) | 1985-09-03 | — | — | US | disclosed |
| EP-0065884-A1 | Urethral catheter capable of preventing urinary tract infection and process for producing the same | UNITIKA LTD. (JP) | 1982-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296323-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | BAX, GAP43, SMN1; SMN2 | EPHX1 2060/4885CES2 4825/4885THRB 4139/4885 |
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | CCR5, CXCR3, CCR2 | EPHX1 1335/4885CES2 860/4885THRB 814/4885 |
| US-20150025077-A1 | GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM | BAX, GAP43, SMN1; SMN2 | EPHX1 2060/4885CES2 4825/4885THRB 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.